Sign in Subscribe
Diseases

Hepatitis B Virus Research Uncovers New Insights into Liver Cancer and Fatty Liver Disease

Strategic Insights

— 1 min read

In a study published in Scientific Reports, a team of researchers from Mengchao Hepatobiliary Hospital of Fujian Medical University investigated the relationship between hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and metabolic dysfunction-associated fatty liver disease (MAFLD). The study found that concomitant MAFLD in patients with HBV-HCC was observed in 20.4% of cases, and diabetic MAFLD was an independent risk factor associated with poorer overall survival after radical resection.

Key Takeaways:

  • The prevalence of concomitant MAFLD in patients with HBV-HCC was 20.4%, as observed in 172 patients out of 843 with HBV-HCC who underwent radical resection.
  • The study found no significant impact of MAFLD on recurrence-free survival (RFS) or overall survival (OS) rates at 1-, 3-, and 5-years in patients with HBV-HCC.
  • Subgroup analysis revealed significantly lower 1-, 3-, and 5-year rates of RFS and OS in the diabetic MAFLD group compared to the non-diabetic MAFLD group (all P < 0.05).
  • Diabetic MAFLD was an independent risk factor associated with poorer OS after radical resection (HR, 1.444; 95% CI 1.082-2.331, P = 0.032).
  • The study concluded that concomitant diabetic MAFLD is associated with a poor prognosis after radical resection in patients with HBV-HCC.

Statistics:

  • 843 patients with HBV-HCC underwent radical resection between January 2015 and December 2020.
  • 172 (20.4%) patients with HBV-HCC had concomitant MAFLD.
  • Diabetic MAFLD patients had significantly lower RFS and OS rates at 1-, 3-, and 5-years compared to non-diabetic MAFLD patients (all P < 0.05).
  • Diabetic MAFLD patients had an increased risk of poorer OS after radical resection (HR, 1.444; 95% CI 1.082-2.331, P = 0.032).

Sources:

  • Impact of metabolic dysfunction-associated fatty liver disease on survival outcomes in patients undergoing radical resection for hepatitis B virus-related hepatocellular carcinoma. Scientific Reports, 2025,15(1):1-9. (http://www.nature.com/srep/index.html)
  • NewsRx. New Findings in Hepatitis B Virus Described from Mengchao Hepatobiliary Hospital of Fujian Medical University (Impact of metabolic dysfunction-associated fatty liver disease on survival outcomes in patients undergoing radical resection for ...). Hepatitis Weekly. June 9, 2025; p 212.

Read more